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Mucopolysaccharidosis type IIIA (MPSIIIA) is a lyso-
somal storage disorder caused by mutations in 
N- sulfoglucosamine sulfohydrolase (SGSH), resulting 
in heparan sulfate (HS) accumulation and progres-
sive neurodegeneration. There are no treatments. We 
previously demonstrated improved neuropathology 
in MPSIIIA mice using lentiviral vectors (LVs) overex-
pressing SGSH in wild-type (WT) hematopoietic stem 
cell (HSC) transplants (HSCTs), achieved via donor 
monocyte/microglial engraftment in the brain. How-
ever, neurological disease was not corrected using 
LVs in autologous MPSIIIA HSCTs. To improve brain 
expression via monocyte/microglial specificity, LVs 
expressing enhanced green fluorescent protein (eGFP) 
under ubiquitous phosphoglycerate kinase (PGK) or 
myeloid-specific promoters were compared in trans-
planted HSCs. LV-CD11b-GFP gave significantly higher 
monocyte/B-cell eGFP expression than LV-PGK-GFP or 
LV-CD18-GFP after 6 months. Subsequently, autolo-
gous MPSIIIA HSCs were transduced with either LV-
PGK-coSGSH or LV-CD11b-coSGSH vectors expressing 
codon-optimized SGSH and transplanted into MPSIIIA 
mice. Eight months after HSCT, LV-PGK-coSGSH vectors 
produced bone marrow SGSH (576% normal activity) 
similar to LV-CD11b-coSGSH (473%), but LV-CD11b-
coSGSH had significantly higher brain expression (11 
versus 7%), demonstrating improved brain specificity. 
LV-CD11b-coSGSH normalized MPSIIIA behavior, brain 
HS, GM2 ganglioside, and neuroinflammation to WT 
levels, whereas LV-PGK-coSGSH partly corrected neuro-
pathology but not behavior. We demonstrate compel-
ling evidence of neurological disease correction using 
autologous myeloid driven lentiviral-HSC gene therapy 
in MPSIIIA mice.
Received 24 January 2013; accepted 30 May 2013; advance online  
publication 16 July 2013. doi:10.1038/mt.2013.141
INTRODUCTION
Mucopolysaccharidosis type IIIA (MPSIIIA) is a neurodegen-
erative lysosomal storage disease caused by mutations in the 
N-sulfoglucosamine sulfohydrolase (SGSH) gene, resulting in a 
deficiency in the enzyme SGSH (EC 3.10.1.1).1 SGSH deficiency 
leads to accumulation of highly sulfated heparan sulfate (HS), 
resulting in cellular and organ dysfunction, particularly in the 
brain.1–4 Patients present in the first decade of life, with progres-
sive failure to achieve developmental milestones, severe behav-
ioral changes, including hyperactivity and sleep disturbances, and 
cognitive and later motor function decline with death in the sec-
ond decade of life, although disease severity varies significantly.1,5,6 
Disease neuropathology involves multiple factors including HS 
storage and sulfation,2–4 secondary storage substrates,4,7,8 neuroin-
flammation,4,9–12 synaptic changes,4 and possibly others.
There is no treatment for MPSIII, however, patients with MPSI 
Hurler, a similar lysosomal storage disorder, often receive hema-
topoietic stem cell (HSC) transplant (HSCT).13–16 Donor HSCs 
repopulate the recipient and secrete enzyme which cross-corrects 
cells in the periphery. Enzyme cannot cross the blood–brain bar-
rier; however, monocytes traffic from the blood into the brain 
where they differentiate into microglial cells and mediate cross-
correction in the central nervous system.17 If treated early in life, 
HSCT mediates significant improvements in cognitive function, 
life expectancy, and peripheral joint and bone disease in MPSI 
patients.13,14,16 HSCT in MPSIIIA patients results in increased 
lifespan but no significant neurological correction,18–20 and HSCT 
produces similar results in MPSIIIA mice.3
Several lines of evidence suggest that HSCT treatment failure 
in MPSIIIA is due to insufficient enzyme produced by donor-
derived microglia in the brain. Studies in other neurological met-
abolic diseases have shown that ex vivo lentiviral transduction of 
autologous HSCs with a missing transgene can correct most of 
the pathological features of the mouse model of MPSI,21 where 
HSCT was less effective, and also metachromatic leukodystrophy, 
where 10% of normal brain enzyme and neuronal correction was 
achieved.22 These preclinical studies in neurological diseases have 
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resulted in ongoing clinical trials in metachromatic leukodystro-
phy and X-linked adrenoleukodystrophy23 among others soon to 
commence.
In a previous work, we demonstrated partial neurological 
correction of MPSIIIA mice using lentiviral-transduced wild-
type (WT) cells; but lentiviral-transduced autologous MPSIIIA 
cells (autologous lentiviral (LV)-HSC gene therapy) were unable 
to mediate neurological correction, and this appears to be due 
to insufficient enzyme production in the brain.3 Complete nor-
malization of neuronal pathology coupled with behavioral nor-
malization has never been achieved in this mouse model to our 
knowledge. We hypothesized that improving monocyte/microg-
lial enzyme expression could make autologous HSC gene therapy 
more brain specific and efficient, thus correcting neurological dis-
ease in MPSIIIA mice.
Here, we report that the myeloid-specific CD11b promoter, in 
the clinically relevant pCCL LV,24 mediates increased monocyte-
specific enhanced green fluorescent protein (eGFP) expression 
over ubiquitous phosphoglycerate kinase (PGK) or myeloid CD18 
promoters in HSCT. Furthermore, transduction of autologous 
MPSIIIA HSCs with a LV expressing codon-optimized SGSH 
under CD11b, mediated normalization of abnormal open-field 
behavior, brain HS, secondary storage, lysosomal compartment 
size, and neuroinflammation in MPSIIIA mice, whereas a PGK 
driven vector could only mediate partial correction in many of 
these parameters. Increased monocyte expression resulted in 
improved brain enzyme without changing peripheral enzyme 
overexpression, making the CD11b vector potentially safer and 
more target specific for the brain. We report neurological correc-
tion of the MPSIIIA mouse model that is achieved with a clinically 
relevant protocol and vector copy numbers (VCNs) of 1.2 per cell 
via autologous LV-HSC gene therapy.
RESULTS
The CD11b promoter increases lentiviral eGFP 
expression in CD11b+ and CD19+ peripheral blood 
leukocytes 6 months after transplantation of gene-
modified HSCs
In order to improve brain-targeted gene expression for the pri-
marily neurological presentation of MPSIIIA, we constructed 
LVs containing eGFP under the myeloid-specific human CD18 
(LV-CD18) or CD11b (LV-CD11b) promoters, or the ubiqui-
tous human PGK-1 promoter (LV-PGK) (Figure 1a),25,26 using 
the pCCL backbone.24 Monocyte/macrophage lineages express 
high levels of CD11b and CD18 peripherally and also within the 
brain where they engraft as microglial cells. Lineage-depleted WT 
murine bone marrow was transduced ex vivo with these vectors 
and transplanted into WT mice (Figure 1b). Colony-forming unit 
(CFU) potential and % transduction of cells were also assessed 
(Supplementary Figure S1a–d). Donor peripheral blood chime-
rism, between 94 and 100%, was achieved 6 months post-trans-
plantation (Figure 1c). On average, 79–87% donor cells were 
eGFP+ with no significant differences between promoters (Figure 
1c). The VCN was significantly higher with LV-CD18 than either 
LV-CD11b (P = 0.01) or LV-PGK (P = 0.0001) with no signifi-
cant difference in copy number between the latter two promot-
ers (Figure 1c). The eGFP expression in leukocytes, 24 weeks 
post-transplant, was significantly higher in LV-CD11b–trans-
duced peripheral blood leukocytes than LV-CD18 (P = 0.0004) or 
LV-PGK (P = 0.03) (Figure 1d) with significantly higher expres-
sion by LV-CD11b in CD11b+ cells compared with LV-CD18 (P = 
0.000077) or LV-PGK (P = 0.003) and in CD19+ cells compared 
with LV-CD18 (P = 0.000017) and LV-PGK (P = 0.0014) (Figure 
1e). The CD11b promoter yielded the highest mean fluorescent 
intensity:VCN ratio in CD11b+ cells, while the CD18 promoter 
had the lowest (Supplementary Figure S1e–g). Comparison of 
LV-CD11b– and LV-PGK–transduced mice with similar copy 
numbers revealed equivalent levels of eGFP expression, except in 
CD11b+ cells where CD11b promoter expression was significantly 
(67%) higher than PGK (Figure 1f–h). LV-eGFP–transduced 
donor cells with microglial morphology were readily detected in 
the brain (Supplementary Figure S1h).
Codon optimization enhances human SGSH activity 
in a human microglial cell line
Human SGSH cDNA and codon-optimized human SGSH 
(coSGSH) cDNA were cloned into pCCL LV under either the 
human CD11b or PGK promoter (Figure 2a). Relative SGSH 
activity was assessed in vitro by transiently transfecting the human 
CHME3 microglial cell line with plasmids containing human 
SGSH or coSGSH under the ubiquitous PGK promoter (Figure 
2b and Supplementary Figure S2a,b). Codon optimization sig-
nificantly (P = 0.0001) increased SGSH activity by 50% in microg-
lial cells.
Ex vivo autologous LV-HSC gene therapy in MPSIIIA 
mice is safe and efficient
In order to determine if ex vivo transduction of MPSIIIA HSCs 
can effectively treat the mouse model of MPSIIIA, MPSIIIA HSCs 
were transduced with the myeloid-enhanced LV-CD11b-coSGSH 
vector (LV-CD11b) or ubiquitous LV-PGK-coSGSH (LV-PGK) 
vector and transplanted into busulfan myeloablated 6- to 8-week-
old female MPSIIIA mice (n = 15) (Figure 2c). WT and MPSIIIA 
littermate controls were used for comparison (n = 15). At 4 months 
of age, 2 months post-transplantation, the VCN was determined 
in white blood cells by quantitative PCR (Figure 2d,e). Higher 
copy numbers were achieved with LV-CD11b than LV-PGK in 
the behavioral cohort: 1.2 versus 0.5 copies/cell, respectively, (P < 
0.001) (n = 8–12) (Figure 2d) and in the biochemistry and histol-
ogy cohort: 1.3 and 0.5 copies/cell (n = 5) (P < 0.001) (Figure 2e). 
At 6 months of age, 91–92% donor peripheral blood chimerism 
was achieved for LV-CD11b and LV-PGK, respectively, with no 
significant difference between them (Figure 2f). At 8 months 
of age, mice were killed, bone marrow was isolated from WT, 
LV-CD11b, and LV-PGK groups and the CFUs were assessed 
using methylcellulose culture (n = 3). There was neither signifi-
cant difference in the total number of CFUs (Supplementary 
Figure S2d) nor in the percentage of CFUs of different lineages 
(Supplementary Figure S2c).
LV-CD11b, but not LV-PGK, corrects open-field 
behavior of MPSIIIA mice
At 6 months of age, the 1-hour open-field test was per-
formed  to  determine the effect of treatment on behavior27 
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(Figure  2g–j; Supplementary Video S1 and Supplementary 
Figure S2e,f). MPSIIIA mice were hyperactive with signifi-
cantly increased path length (P = 0.002) (Figure 2g), increased 
frequency (P = 7.3 × 10−5) (Figure 2i), and with a duration of 
motion over 100 mm/second (P = 0.002) (Figure 2j). MPSIIIA 
mice also have a reduced sense of danger, shown by significantly 
increased frequency of entries into the centre of the open field 
(P = 0.022) (Figure 2h).
Figure 1 Comparison of eGFP expression from myeloid promoters. (a) pCCL LVs containing human CD18, CD11b, and PGK promoters driving 
eGFP expression. (b) WT bone marrow was lineage depleted and the enriched stem cell population transduced with LV-hCD18-eGFP, LV-hCD11b-
eGFP, or LV-hPGK-eGFP at an MOI of 40–70 and transplanted into myeloablated WT mice. n = 8–10 (c) Donor and eGFP+ chimerism was determined 
24 weeks post-transplantation. The vector copy number (VCN) was determined in WBCs. (d–e) Mean fluorescent intensity of eGFP expression was 
determined for all leukocytes and for CD11b+, CD19+, and CD3+ cells 24 weeks post-transplantation. (f–h) Mice with most equivalent copy numbers 
(VCN of 2.3–4.1) in WBCs were further compared. Error bars represent the SEM. Significant differences between the two groups marked with a line 
are demonstrated with *P < 0.05; **P < 0.01; and ***P < 0.001. CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; hPGK, human 
phosphoglycerate kinase; LV, lentiviral vector; MOI, multiplicity of infection; ns, nonsignificant; WBC, white blood cell; WT, wild-type.
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LV-PGK had no significant effect on MPSIIIA behavior. In con-
trast, LV-CD11b fully normalized hyperactive behavior to WT levels 
with significant differences to MPSIIIA in all measures: path length 
(P = 0.016) (Figure 2g), frequency (P = 0.004) (Figure 2i), duration of 
motion over 100 mm/second (P = 0.025) (Figure 2j), and frequency 
of centre entries (P = 0.037) (Figure 2h). LV-CD11b was signifi-
cantly better than LV-PGK in path length (P = 0.007) (Figure 2g), 
frequency (P = 0.015) (Figure 2i), and duration of motion over 
100 mm/second (P = 0.002) (Figure 2j) but not in centre entries.
LV-CD11b improves brain-specific SGSH activity over 
LV-PGK and corrects primary HS storage of MPSIIIA 
mice
At 8 months of age, SGSH enzymatic activity was measured in 
perfused mice. LV-CD11b and LV-PGK significantly increased 
SGSH activity to 472% of WT (P = 5.1 × 10−12) and 576% (P = 
3.5 × 10−12), respectively, in bone marrow (Figure 3a) and to 162% 
of WT (P = 2.4 × 10−11) and 245% (P = 6.0 × 10−12), respectively, in 
the spleen (Figure 3b). In the liver (Figure 3c), LV-CD11b and 
Figure 2 LV-CD11b–modified autologous hematopoietic stem cells correct MPSIIIA mouse behavior. (a) pCCL LVs were made containing either 
human CD11b or hPGK promoters driving normal or coSGSH. (b) Expression of hSGSH and coSGSH was compared by transient transfection of the 
human CHME3 microglial cell line. (c) MPSIIIA bone marrow was lineage depleted and transduced with LV-hCD11b-coSGSH or LV-hPGK-coSGSH at 
an MOI of 80, then transplanted into busulfan myeloablated MPSIIIA mice. (d,e) VCN was determined in WBCs (behavior n = 8–12; biochemistry n 
= 5). (f) 4 months post-transplantation, the donor chimerism in WBCs was determined by flow cytometry (n = 3–7). (g–j) Open-field behavior was 
evaluated at 6 months (24 weeks) of age (n = 8–15 female mice per group). The measures of hyperactivity were: (g) path length, (i) frequency, and (j) 
duration spent moving over 100 mm/second, while (h) frequency of centre entries measures thigmotaxis and may be a measure of sense of danger. 
Error bars represent the SEM. Significant differences to MPSIIIA, between the two groups marked with a line, are demonstrated with *P < 0.05; **P < 
0.01; and ***P < 0.001. CMV, cytomegalovirus; coSGSH, codon-optimized human N-sulfoglucosamine sulfohydrolase; hPGK, human phosphoglycer-
ate kinase; hSGSH, human N-sulfoglucosamine sulfohydrolase; LV, lentiviral vector; MOI, multiplicity of infection; MPSIIIA, mucopolysaccharidosis 
type IIIA; VCN, vector copy number; WBC, white blood cell; WT, wild-type.
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LV-PGK significantly increased SGSH activity to 60% of WT (P 
= 6.5 × 10−9) and 66% (P = 5.7 × 10−9), respectively. In the periph-
eral organs, there was no significant difference in SGSH activity 
between LV-CD11b and LV-PGK. However, in the brain (Figure 
3d), LV-CD11b significantly increased SGSH activity to 11% of 
WT (P = 2.2 × 10−6), which was significantly higher than LV-PGK 
(P = 0.024), at 7% of WT (P = 7.3 × 10−4).
Increased lysosomal compartment size results in upregu-
lation of other lysosomal enzymes by the transcription factor 
EB,28 therefore, β-N-acetyl hexosaminidase (β-Hex) activity was 
also measured in liver (Figure 3e) and brain (Figure 3f). Both 
LV-CD11b and LV-PGK significantly reduced β-Hex activity to 
normal levels (liver P = 9.8 × 10−7, P = 1.0 × 10−6, respectively; brain 
P = 2.1 × 10−5, P = 6.6 × 10−4, respectively).
Total glycosaminoglycan (GAG) measured by Blyscan was 
1.6-fold elevated in MPSIIIA brain and significantly reduced by 
both the treatments (Figure 3g). Total HS determined by 2-ami-
noacridone–labeled disaccharide analysis was 18-fold elevated 
in MPSIIIA mouse brains (Figure 3h). LV-CD11b significantly 
corrected HS in the brain (P = 0.003) to a level where it was no 
Figure 3 LV-CD11b improves brain-specific SGSH activity over LV-PGK and corrects primary HS storage of MPSIIIA mice. At 8 months of age, 
SGSH enzyme activity was measured in (a) bone marrow, (b) spleen, (c) liver, and (d) brain of perfused mice (n = 5). Secondary upregulation of 
β-Hex was measured in (e) liver and (f) brain. (g) Total sulfated GAG in the brain was measured with the dye binding Blyscan assay. (h) Total HS 
storage was measured by 2-aminoacridone (AMAC)–labeled disaccharide analysis. The different HS disaccharides were quantified by (i) AMAC, and 
(j) the relative proportion of HS that was NAc, NS, 6S, and 2S was also determined. Error bars represent the SEM. Significant differences to MPSIIIA 
are marked with *P < 0.05 and ***P < 0.001. Treatments that are not significantly different to WT are marked with a line and ns (nonsignificant) (P 
> 0.05). 6S, 6-O-sulfated; 2S, 2-O-sulfated; β-Hex, β-N-acetyl hexosaminidase; GAG, glycosaminoglycan; HS, heparan sulfate; LV, lentiviral vector; 
MPSIIIA, mucopolysaccharidosis type IIIA; NAc, N-acetylated; NS, N-sulfated; PGK, phosphoglycerate kinase; SGSH, N-sulfoglucosamine sulfohydro-
lase; WT, wild-type.
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longer significantly different from WT. LV-PGK did not signifi-
cantly reduce HS (P = 0.057), remaining significantly elevated 
over WT (P = 0.001). HS sulfation has an important functional 
role, thus HS disaccharides were quantified (Figure 3i). There 
was a significant increase in highly sulfated HexA(2S)-GlcNS(6S) 
and HexA(2S)-GlcNS (P = 1.4 × 10−10 and P = 3.6 × 10−9, respec-
tively) and a commensurate reduction in HexA-GlcNS and HexA-
GlcNAc (P = 5.6 × 10−8 and P = 1.1 × 10−7, respectively) between 
WT and MPSIIIA. There was no significant difference between 
WT and MPSIIIA in HexA-GlcNS(6S) or HexA-GlcNAc(6S) 
HS disaccharides. LV-CD11b normalized HexA(2S)-GlcNS and 
HexA-GlcNAc and significantly corrected HexA(2S)-GlcNS(6S) 
and HexA-GlcNS. LV-PGK also improved the four abnormal HS 
disaccharides but only corrected HexA-GlcNAc.
Overall, HS from MPSIIIA mouse brain is significantly 
N-sulfated (P = 2.7 × 10−8), 6-O-sulfated (6S) (P = 2.1 × 10−10), and 
2-O-sulfated (2S) (P = 2.4 × 10−10) with a commensurate reduction 
in un-sulfated N-acetylated (NAc) (P = 3.4 × 10−8) HS (Figure 3j). 
LV-CD11b normalized NAc, N-sulfated, and 2S HS to WT levels 
and significantly corrected 6S (P = 9.5 × 10−8) HS. LV-PGK cor-
rected NAc and N-sulfated HS, but was only able to reduce 2S (P = 
7.1 × 10−8) and 6S (P = 4.5 × 10−8) HS.
LV-CD11b normalizes the neuronal lysosomal 
compartment and most areas of neuroinflammation, 
while both LV-CD11b and LV-PGK mediate 
improvements in secondary brain markers in MPSIIIA 
mice
To determine the effects of increased SGSH on the neuronal lyso-
somal compartment, the lysosomal stain LAMP2 (green) was 
colocalized with neuronal cells using NeuN (red) (Figure 4). 
In MPSIIIA NeuN-positive cells, there was intense coregistered 
cytoplasmic staining of lysosomes, whereas in WT mice, LAMP2 
staining was weaker, punctuate, and perinuclear. LV-CD11b 
appeared to correct this to WT levels and LV-PGK also medi-
ated correction of the majority of this in the cerebral cortex 
(Figure 4a). We also characterized the medial nucleus region of 
the amygdala as we previously found this region of the brain to 
be less well corrected by gene therapy than the cerebral cortex3 
and it is involved in processing memory, emotional responses, and 
behavior.29 The lysosomal compartment was also intensely stained 
in MPSIIIA compared with WT mice and a significant propor-
tion of staining was in NeuN-negative cells, although this could 
reflect slightly lower neuronal density. In the amygdala and the 
rest of the brain, the lysosomal compartment appeared normal in 
LV-CD11b–treated mice (Figure 4b), whereas LV-PGK had less 
effect in correcting abnormal LAMP2 staining than LV-CD11b.
Severe neuroinflammation is present throughout the MPSIIIA 
brain4,9 (Supplementary Figure S3). There were 8.9-fold more 
isolectin B4 (ILB4)-positive microglia than normal in MPSIIIA 
cerebral cortex (Figure 5a). LV-CD11b normalized microglial 
numbers to WT levels in cortex (P = 2.7 × 10−7), while LV-PGK 
reduced them from MPSIIIA (P = 2.0 × 10−4) but was still signifi-
cantly elevated above WT levels (P = 0.004). A 64-fold increase 
in ILB4-positive microglia in MPSIIIA mice was observed in the 
medial nucleus region of the amygdala (Figure 5b). LV-CD11b 
corrected (P = 0.0004) the number of microglia and LV-PGK 
reduced the number (P = 9.5 × 10−6) but these remained signifi-
cantly elevated (P = 0.007). Despite normalization by CD11b in 
these brain regions, elevated numbers of microglial cells remained 
in other brain regions including the globus pallidus, thalamus, 
and hypothalamus, although all were much improved over either 
PGK or MPSIIIA (Supplementary Figure S3). There were 25-fold 
more astrocytes than normal in MPSIIIA cerebral cortex (Figure 
5c). LV-CD11b normalized astrocyte numbers in the cortex (P = 
1.9 × 10−7), and mostly throughout the brain, whereas LV-PGK 
significantly reduced them from MPSIIIA (P = 4.2 × 10−4) but 
was still significantly elevated above WT (P = 0.0018) and above 
LV-CD11b levels (P = 0.018). A twofold increase in astrocytes in 
MPSIIIA mice was observed in amygdala (Figure 5d). LV-CD11b 
and LV-PGK both normalized astrocyte numbers.
MPSIIIA is also characterized by secondary storage of GM2 
ganglioside in the brain, particularly in lamina II/III and V/VI 
Figure 4 LV-CD11b corrects lysosomal compartment size in MPSIIIA 
brains. Representative confocal images of (a) brain cortex (layer IV/V) 
and (b) amygdala (medial nucleus) from approximately −1.18 mm rela-
tive to bregma were stained with LAMP2 for lysosomal compartment 
(green) and NeuN for neuronal nuclei (red), and representative images 
are shown. Bar = 20 µm. LV, lentiviral vector; MPSIIIA, mucopolysacchari-
dosis type IIIA; PGK, phosphoglycerate kinase; WT, wild-type.
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of the primary motor, somatosensory, and parietal areas of cere-
bral cortex and amygdala with no staining detected in WT mice 
(Supplementary Figure S4).4 LV-CD11b and LV-PGK both 
(P = 4.3 × 10−8 and P = 1.4 × 10−7, respectively) corrected GM2 
ganglioside storage in the cerebral cortex (Figure 6a). GM2 
ganglioside storage was nearly sevenfold elevated in amygdala 
of MPSIIIA mice and was completely cleared by LV-CD11b 
(Figure 6b), but it was only reduced with LV-PGK. Again, 
despite normalization in these brain regions, LV-CD11b showed 
mild elevations of GM2 ganglioside staining in other brain 
regions including globus pallidus, thalamus, and retrosplenial 
granular cortex. LV-PGK showed more significant GM2 gan-
glioside staining in these regions, particularly in the amygdala, 
and untreated MPSIIIA were worse again (Supplementary 
Figure S4).
Presynaptic vesicle dysregulation has also been observed 
in the MPSIIIA brain via changes in VAMP2 from punctate 
vesicular staining to diffuse.4 LV-CD11b and LV-PGK both sig-
nificantly (P = 1.4 × 10−5 and P = 8.0 × 10−5, respectively) cor-
rected VAMP2 localization in the cerebral cortex (Figure 6c). 
We  observed no  statistical differences in VAMP2 staining in 
amygdala (Figure 6d).
Figure 5 LV-CD11b normalizes neuroinflammation in the cerebral cortex and amygdala of MPSIIIA mice, while LV-PGK mediates improve-
ments in neuroinflammation. Four brain sections per mouse (n = 5 per group), taken from approximately bregma 0.26, −0.46, −1.18, and 
−1.94 mm, were stained and quantified with isolectin B4 for microglia number in the (a) cerebral cortex and (b) amygdala or with GFAP for astrocytes 
in the (c) cerebral cortex and (d) amygdala. Representative images from the cerebral cortex (layer IV/V) and the amygdala, both from approximately 
−1.18 mm relative to bregma, are shown. Sections were counterstained with Mayer’s hematoxylin to highlight the nuclei (blue). Error bars represent 
the SEM. Significant differences to MPSIIIA, between the two groups marked with a line, are demonstrated with *P < 0.05, **P < 0.01; and ***P < 
0.001. Bar = 50 µm. LV, lentiviral vector; MPSIIIA, mucopolysaccharidosis type IIIA; PGK, phosphoglycerate kinase; WT, wild-type.
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DISCUSSION
This study demonstrates neurological and open-field behavioral 
correction of the mouse model of MPSIIIA using a clinically 
relevant therapeutic approach. The CD11b promoter enhanced 
eGFP expression in CD11b+ and CD19+ cells in contrast to 
CD18, which was more specific but less effective than PGK or 
CD11b. Both myeloid promoters were previously evaluated in 
retroviral vectors with poor expression in cell lines compared 
with ubiquitous promoters.30 We also found myeloid promoters 
to be ineffectual in monocyte/macrophage cell lines, and it was 
only in hematopoietic cells in vivo that CD11b expression was 
high. We achieved slightly higher copy numbers from CD11b 
vectors than PGK vectors, however, by comparing CD11b-eGFP 
and PGK-eGFP mice with similar copy numbers (average: 3.77, 
3.01 respectively; nonsignificant), we found that CD11b pro-
moter yielded 67% significantly higher expression in CD11b+ 
cells (33,199 versus 19,846; P < 0.05), with no significant differ-
ences in other lineages (Figure 1f–h).
The LV-CD11b vector mediated significant improvements 
in SGSH expression with 11% of WT activity in the entire brain 
via monocyte/microglial-enhanced expression in brain engrafted 
cells compared with 7% using the ubiquitous PGK promoter. The 
Figure 6 LV-CD11b and LV-PGK both correct secondary storage and presynaptic vesicles in the cerebral cortex, while LV-PGK is less effec-
tive in the amygdala of MPSIIIA mice. Four brain sections per mouse (n = 5 per group), taken from approximately bregma 0.14, −0.58, −1.3, and 
−2.06 mm, were stained and quantified for GM2 ganglioside in the (a) cerebral cortex and (b) amygdala, and VAMP2 for presynaptic vesicles in 
the (c) cerebral cortex and (d) amygdala. Representative images from the cerebral cortex (layer IV/V) and the amygdala, both from approximately 
−1.3 mm relative to bregma, are shown. Error bars represent the SEM. Significant differences to MPSIIIA, between the two groups marked with a line, 
are demonstrated with ***P < 0.001. Bar = 50 µm. LV, lentiviral vector; MPSIIIA, mucopolysaccharidosis type IIIA; PGK, phosphoglycerate kinase; WT, 
wild-type.
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difference was sufficient to mediate correction of hyperactive 
behavior in LV-CD11b–treated mice with no change in LV-PGK–
treated mice. Analysis of SGSH brain enzyme levels across all 
treated MPSIIIA mice3 allowed us to determine the minimal effec-
tive brain enzyme level mediating behavioral normalization, to be 
~8.5% of normal enzyme activity (data not shown).
We achieve a similar level of brain SGSH activity to that 
reported after intravenous adeno-associated virus serotype-9 
expressing SGSH in MPSIIIA mice (6–12%).11 In this paper, activ-
ity was lower in female mouse brains (6–8%), at levels we would 
predict to be subtherapeutic, while behavior was not evaluated. 
In addition, 8–17% activity was reported following direct brain 
injection of adeno-associated virus serotype-2/5 expressing 
SGSH/SUMF1 in MPSIIIA mice10 but injection site-localized sub-
strate correction was reported in this case. The efficacy of both 
approaches could be reduced on scale-up due to reliance on vector 
correction of brain cells and because enzyme is not reported to 
cross the blood–brain barrier in significant quantity.31 In contrast, 
donor microglia are distributed throughout the brain follow-
ing autologous LV-HSC gene therapy, and clinical experience in 
immunodeficiencies32 suggests that mouse–human scale-up is not 
problematic. The GAG dye binding assay gives a misleading indi-
cation of correction by LV-PGK in the brain (Figure 3g), whereas 
the 2-aminoacridone assay measuring HS via high-performance 
liquid chromatography is much more sensitive and showed that 
LV-PGK had reduced excess HS, but not significantly to WT levels 
(Figure 3h). Although the GAG assay is commonly used, preclin-
ical demonstrations of neurological correction in MPS diseases 
should rely on measurements of brain HS in the context of several 
other markers as well as demonstrable behavioral correction.
Neuroinflammation in terms of microglial and astrocyte 
cell numbers was almost completely corrected by LV-CD11b 
in both the cortex and amygdala, and significantly improved 
throughout the brain in contrast to our previous findings.3 
Neuroinflammation was only partially corrected by LV-PGK. 
Amygdala was studied because we had previously observed 
incomplete correction of secondary pathology and neuroinflam-
mation in this region.3 Notably, in MPSIIIA, the amygdala has 
significantly increased microglial activation over cortex (64-fold 
versus ninefold), with comparatively lower astrocytosis (twofold 
versus 25-fold). Neuroinflammation is very much a global phe-
nomenon in the MPSIIIA mouse brain, thus it is intriguing that 
certain brain regions retain some inflammation in the LV-CD11b 
mice (Supplementary Figure S3), despite behavioral correction. 
This may reflect the distance of less well corrected areas such as 
the globus pallidus and thalamus from ventricular spaces, which 
we presume are the major routes of delivery for donor monocytes 
into the brain resulting in lower distribution of donor cells in 
these areas.
Secondary storage of GM2 ganglioside was corrected by 
LV-CD11b in cerebral cortex, amygdala, and in most regions of 
the brain and by LV-PGK in the cortex, but staining remained 
in the LV-PGK–treated amygdala and in several other brain 
regions, in line with our previous observations.3 The correction 
of open-field behavior by LV-CD11b but not by LV-PGK could 
be related to the residual staining observed in the amygdala in 
LV-PGK–treated mice for both LAMP2 and GM2 ganglioside 
staining as the amygdala has a role in memory, processing emo-
tions, and behavioral reactions29 and is postulated to play a role in 
the behavior of MPSIIIA patients. In support of this, we observed 
small elevations of GM2 ganglioside staining in the thalamus, ret-
rosplenial granular cortex, and the hypothalamus, but not in the 
amygdala of LV-CD11b–treated mice. However, we also observed 
neuroinflammatory differences between LV-CD11b and LV-PGK 
in both cerebral cortex and amygdala; moreover, in a previous 
study, where behavioral correction was observed, GM2 ganglio-
side storage was still present in the amygdala, which suggests that 
GM2 ganglioside storage in this region is not the primary cause 
of pathology.3 In our previous study, we observed behavioral cor-
rection with only partially corrected neuroinflammation, thus 
we would hypothesize that differences in primary storage of HS 
and lysosomal function may be more important in determining 
behavioral changes. Although HS has a role in stimulating inflam-
mation via Toll-like receptor 4, ablation of Toll-like receptor 4 
or downstream MyD88 signaling in the similar mouse model of 
MPSIIIB delayed neuroinflammation, but not the appearance of 
other markers of neurodegeneration.33 HS, GM2 and GM3 gangli-
osides could instead act as danger-associated molecular patterns, 
exacerbating inflammation via both Toll-like receptor-mediated 
and antigen-driven adaptive immune responses.34,35 Although we 
know that excess HS is present outside cells in plasma and urine of 
patients with MPS diseases,36–39 critical to the implication of HS in 
Sanfilippo disease pathology would be the identification of a func-
tional role for the primary HS storage material in neuropathology.
Overall, LV-CD11b corrected many pathological markers 
to, or near to, WT levels in most areas of the brain. In contrast, 
LV-PGK had lower brain enzyme expression, which resulted in 
sustained elevation of pathological markers in many brain areas. 
Open-field behavior was much more biphasic, and this may reflect 
a functional threshold effect at the cellular level, where clearance 
of pathological markers to a certain level resolves function, rather 
than specific brain areas being responsible for neuropathology.
Of note, the normalization in the number of activated microg-
lia in the cortex and amygdala by LV-CD11b did not impact on 
enzyme delivery. Although this study was not setup to answer this 
question, donor microglial repopulation could be independent of 
microgliosis. Busulfan conditioning results in 22% donor-derived 
Iba1+ microglial repopulation of the brain or 30% CD11b+CD45lo 
donor-derived mcroglia,40,41 but donor cells may not be respon-
sible for microgliosis. There is also a potential contribution from 
CD11b+ neutrophils to brain enzyme activity as these are also 
known to traffic into the brain.
Most studies evaluating autologous LV-HSC gene therapy have 
utilized ubiquitous promoters. The PGK promoter was used in 
MPSI mice to drive expression of IDUA and resulted in 100-fold 
overexpression of IDUA activity in peripheral blood mononu-
clear cells. This was achieved with copy numbers of 11 per cell.21 
Although overexpression of IDUA was not shown to be toxic, it 
could impact on other gene products. In MPSI, higher than normal 
levels of IDUA may be beneficial in treating the skeletal manifesta-
tions, but in primarily neurological disorders, enhancing expression 
in the brain while limiting peripheral overexpression is a prudent 
safety approach. Indeed, in the mouse model of Krabbe disease, 
GALC expression was found to be toxic to HSCs and progenitors, 
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forcing a micro RNA-regulated approach to therapy.42 In this study, 
we achieved significantly higher enzyme levels in the brain with the 
CD11b promoter compared with PGK and similar enzyme levels in 
the periphery with both promoters (5-fold over normal). Notably, 
LV-CD11b–mediated neurological correction was achieved with 
clinically relevant copy numbers per cell of 1.2. We had higher 
copy numbers in CD11b- versus PGK-treated MPSIIIA mice, but 
increased PGK copy number would have also resulted in increased 
peripheral overexpression between tenfold and 15-fold of normal, 
and was not achievable in our hands with this promoter. Although 
peripheral overexpression may not be an issue with SGSH or IDUA, 
wider application of this approach as a neurological disease treat-
ment makes the targeted myeloid-specific approach a safer and more 
specific alternative. Neurological correction of the mouse model of 
metachromatic leukodystrophy was achieved with only 10% brain 
enzyme and this and other work has resulted in subsequent clinical 
trials.22,23 On the basis of these and our own demonstration of pre-
clinical efficacy, we propose a myeloid driven autologous HSC gene 
therapy approach to treat MPSIIIA patients.
MATERIALS AND METHODS
Mice.  In vivo procedures were ethically approved under UK Home Office 
regulations and PPL 40/3117. MPSIIIA mice7 on a C57BL/6J background 
(B6.Cg-Sgshmps3a/6J) were maintained by heterozygote breeding.3,4,27 
MPSIIIA backcrossed to PEP3 CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) were 
used to distinguish donor and recipient cells as previously described.3 WT 
littermate controls were used throughout.
Construction of LVs. The SGSH gene flanked with Att B1/2 sites was 
inserted into BamHI/SalI restriction sites in the third-generation LV #277 
pCCLsin.cPPT.hPGK.eGFP.Wpre22 in place of eGFP. Human CD11b and 
CD18 promoters were amplified from human gDNA from peripheral 
blood. Primers were based on sequences from GenBank: M77675.1 for the 
CD18 promoter and M84477 for the CD11b promoter25,26 – CD11b for-
ward 5′-CTCGAGGATATC ATTTTTTTGTAGAGACAGGGTCTCT-3′; 
CD11b Rev 5′-GGATCC GGCTGGAAGGAGCCAGAA-3′; CD18 forward 
5′-CTCGAGGATATC TGGCCTCTGTGTTCTTCTTC-3′, CD18 Rev 
5′-GGATCC CCTCGGTGTGCTGGAGTC-3′. Promoters were exchanged 
with PGK in the LV backbone at XhoI and BamHI sites.
SGSH was codon optimized by Life Technologies (Paisley, UK), 
and cloned into LV-PGK and LV-CD11b using Gateway cloning (Life 
Technologies).
 The start codon and promoter of WPRE X protein were mutated to 
the mut6 configuration43 by exchange of the SalI/SacII fragment from pHR.
SFFV.SGSH.3
LV production and titration. The LV was produced as previously described 
by transient transfection of HEK 293T cells with pMD2G, p∆8.91gag/pol, 
and the LV plasmid.3,44,45 LV was titered using quantitative PCR.3 EL4 mouse 
lymphoma cells (ATCC no. TIB-39; ATCC, Manassas, VA) were transduced 
with three dilutions of concentrated LV and collected 72 hours later. DNA 
was extracted using GenElute Mammalian Genomic DNA Miniprep kit 
(Sigma-Aldrich, Poole, UK) and the number of integrated viral genomes 
per cell was determined using quantitative PCR as follows. The TaqMan 
universal PCR master mix (Applied Biosystems, by Life Technologies, 
Paisley, UK) was added with glyceraldehyde 3-phosphate dehydro-
genase forward (5′-TGCACCACCAACTGCTTAGC-3′) and reverse 
(5′-AGAACATCATCCCTGCATCC-3′) primers and a VIC probe (Applied 
Biosystems), and WPRE forward (5′-CCGTTGTCAGGCAACGTG-3′) 
and reverse (5′-AGCTGACAGGTGGTGGCAAT-3′) primers and FAM/
TAMRA probe (5′-TGCTGACGCAACCCCCACTGGT-3′), and a DNA 
template (1 ng). Each sample was run in duplicate. The PCR reaction 
was performed using an ABI PRISM 7700 Sequence detector (Applied 
Biosystems) at the settings: 50 °C for 2 minutes, 95 °C for 10 minutes, fol-
lowed by 40 cycles for 15 seconds, and 60 °C for 1 minute. The data were 
analyzed using sequence Detection System version 1.9.1 software (Applied 
Biosystems). The number of integrations was determined using a standard 
curve generated by serial dilutions of DNA sample derived from an EL4 cell 
line clone (ALS EL4 eGFP 2.2) containing two copies of integrated WPRE 
gene/cell. The VCN in the range of 0.1–5 integrations/cell was used to cal-
culate the titer.
Mouse HSC transduction and transplantation. Performed as previously 
described.3,44,45 Briefly, myeloablative conditioning was two 5 Gy irradia-
tion separated by 4 hours (eGFP) or 125 mg/kg Busulfan (Busilvex; Pierre 
Fabre, Boulogne, France) intraperitoneal over 5 days (MPSIIIA). Mouse 
bone marrow was isolated, lineage depleted (Stem Cell Technologies, 
Grenoble, France), and incubated at 37 °C 5% CO2 in X-Vivo-10 (Lonza, 
Slough, UK), 2% bovine serum albumin (Sigma-Aldrich), 100 ng/ml 
murine SCF (R&D Systems, Abingdon, UK), 100 ng/ml mFlt3-Ligand 
(R&D System), and 10 ng/ml mIL-6 (R&D Systems) for 3 hours before len-
tiviral transduction.
VCN determination. VCN was determined from white blood cells using 
quantitative PCR as previously described.3
Sample processing. At 8 months of age, mice were anesthetized and trans-
cardially perfused with 37 °C Tyrode’s solution to remove blood from 
organs as previously described.3 Pieces of liver and spleen and one hemi-
sphere of brain were frozen at -80 °C. The other brain hemisphere was 
fixed in 4% paraformaldehyde for 24 hours, then 30% sucrose 2 mmol/l 
MgCl2/phosphate-buffered saline for 48 hours before freezing at -80 °C. 
For SGSH and HS assays, samples were homogenized and sonicated in 
homogenization buffer (0.5 mol/l NaCl, 0.02 mol/l Tris pH 7–7.5), then 
centrifuged at 2,200g for 15 minutes at 4 °C, and the supernatant was col-
lected. Protein concentration was determined using Pierce BCA assay kit 
(Fisher Scientific, Loughborough, UK) assay according to manufacturer’s 
instructions.
SGSH enzymatic activity. SGSH enzymatic activity was quantified as pre-
viously described.3 Tissue samples were homogenized and sonicated to 
extract protein, which was measured using Pierce BCA assay kit (Fisher 
Scientific); 60 µg of brain protein, 40 µg of liver, 40 µg of spleen, and 16 
µg of bone marrow protein were analyzed. The assay was performed as 
per manufacturer’s instructions (Moscerdam Substrates, Oegstgeest, the 
Netherlands) with minor modifications. Samples were first incubated 
for 17 hours at 42 °C with SGSH substrate 4-methylumbelliferyl-α-D-
sulfoglucosamine (4-MU-αGlcNS; Moscerdam Substrates), followed by 
24 hours at 37 °C with α-glucosidase enzyme, which resulted in release of 
4-methylumbelliferone fluorescent substance. Fluorescence was measured 
at excitation 360 nm and emission 460 nm using a Synergy HT Microplate 
reader (BioTec, Potton, UK).
Blyscan assay for total GAGs. The Blyscan assay for total sulfated GAGs 
was performed as previously described, except 350 µg of protein was used.3
CFU assay.  At 8 months of age, 6 months post-transplantation, bone mar-
row was isolated from WT, LV-CD11b, and LV-PGK mice and set up in 
MethoCult culture (Stem Cell Technologies) as previously described3,45 to 
assess CFU lineage development.
Open-field behavior. Performed as previously described.3,27,46,47 Each 
mouse was tested at 6 months of age 1.5 hours into the 12-hour light phase 
to ensure the same circadian time point. Mice were dropped into the cen-
tre of an open-field arena (width 450 mm, depth 450 mm, height 500 mm) 
made of matt white acrylic; and behavior was recorded for 1 hour using a 
digital camcorder (Sony, Weybridge, UK). The data were analyzed using 
TopScan suite software version 2.0 (Clever Sys, Reston, VA). The total 
path length, frequency and duration of rapid exploratory behavior (speed 
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>100 mm/s), duration of immobility (speed <5 mm/s), and frequency of 
entering the centre and duration in the centre (75 mm from each edge) 
were analyzed.
2-aminoacridone–labeled disaccharide analysis of HS. Analysis of the 
quantity and sulfation state of HS using 2-aminoacridone labeling and 
high-performance liquid chromatography was determined as previously 
described.2
Immunohistochemistry. Four brain sections per mouse taken from, 
approximately, bregma 0.26, −0.46, −1.18, and −1.94 mm were stained and 
quantified by counting ILB4- or GFAP-positive cells or by measuring stain 
intensity for GM2 gangliosides and VAMP2 as previously described.4,47,48 
LAMP2 staining was performed on sections from approximately −1.18 mm 
relative to bregma as previously described.3
Immunohistochemical staining for GFP, NeuN, and LAMP2. Sections 
were blocked in 5% goat serum, 1 mg/ml bovine serum albumin, and 0.1% 
Triton X-100 in Tris-buffered saline (TBS) for 1 hour, then incubated over-
night at 4 °C with chicken anti-GFP antibody (1:1,000; Abcam, Cambridge, 
UK) or both mouse anti-NeuN IgG (1:100; Millipore, Watford, UK) and 
rat anti-LAMP2 IgG (0.25 µg/ml; developed by August, J, Developmental 
Studies Hybridoma Bank, University of Iowa, Iowa City, IA) in blocking 
solution, washed in TBS, and stained with Alexa 488 goat anti-chicken 
IgG for the GFP primary antibody (1:1,000; Life Technologies) or both 
Alexa 488 goat anti-mouse and Alexa 594 goat anti-rat IgG (1:1,000; Life 
Technologies) in blocking solution for 1 hour in the dark. After wash-
ing with TBS, sections were counterstained with 300 nmol/l DAPI (Life 
Technologies) for 15 minutes. Sections were mounted using ProLong Gold 
Anti-fade mounting medium (Life Technologies).
Immunohistochemical staining for ILB4, GFAP, VAMP2, and GM2 gan-
glioside. Sections were blocked in 3% H2O2 in TBS, followed by blocking in 
10% normal serum in 0.1% Triton X-100 in TBS for 30 minutes, then incu-
bated overnight at 4 °C with rabbit anti-GFAP (1:500; DakoCytomation, 
Ely, UK) or chicken anti-VAMP2 (1:500; Millipore) or anti-GM2 antibody 
(1:40; a gift from Dr Konstantin Dobrenis and Prof Steven Walkey), or 
peroxidase-conjugated ILB4 from Bandeiraea simplicifolia (1:100; Sigma-
Aldrich) in blocking solution, washed 4× in TBS, and, with exception 
for ILB4, stained with the appropriate biotinylated secondary antibody 
(Vector Laboratories, Burlingame, CA) for 2 hours. After washing with 
TBS, sections were incubated with avidin-biotin complex (1:200; Vector 
Laboratories) for 1.5 hours and developed using DAB substrate (Vector 
Laboratories). To obtain black staining, nickel was added to the DAB sub-
strate buffer. For ILB4 staining, 1 mmol/l MgCl2 and CaCl2 were added to 
the buffers. Sections were mounted onto positively charged slides (Fisher 
Scientific) and cover-slipped in DPX medium (Fisher Scientific).
Statistical analysis. JMP software (SAS Institute, Cary, NC) was used with 
one way analysis of variance and Tukey post hoc test for analysis. Where 
standard deviations were unequal, data were log transformed to achieve 
normal distributions. Significance was assumed at P < 0.05.
SUPPLEMENTARY MATERIAL
Figure S1. LV-eGFP transduction does not affect colony-forming 
units, lineage distribution, or brain engraftment.
Figure S2. Additional tests on LV-PGK-SGSH and LV-CD11b-SGSH.
Figure S3. Low power images of isolectin B4 (microglia) staining in 
WT, MPSIIIA, LV-CD11b– and LV-PGK–treated MPSIIIA mouse brain.
Figure S4. Low power images of secondary storage of GM2 ganglio-
side in WT, MPSIIIA, LV-CD11b– and LV-PGK–treated MPSIIIA mouse 
brain.
Video S1. LV-CD11b but not LV-PGK–modified autologous HSCs cor-
rect MPSIIIA mouse behavior.
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